McKesson Medical-Surgical secures $2B credit facility ahead of potential IPO
What's the deal? McKesson Medical-Surgical has secured a $2 billion pro rata credit facility arranged by JPMorgan Chase. The facility comprises a $750 million five-year senior secured Term A loan, a $250 million two-year senior secured Term A loan, and a $1 billion five-year senior secured revolving credit facility.
Proceeds will repay a shareholder loan owed to parent McKesson Corporation.
The financing follows a deal in which Apollo Funds agreed to acquire a minority stake in McKesson's Medical-Surgical Solutions segment through a $1.25 billion convertible preferred equity investment. That transaction values the segment at roughly $13 billion in total enterprise value.
Why now? McKesson is positioning the medical-surgical business for a potential IPO. Establishing an independent capital structure — replacing intercompany loans with third-party credit facilities — is a standard step in carving out a unit ahead of a public listing.
The company scheduled a conference call for May 27, 2026, to walk investors through the capital structure changes and broader strategic direction.
What could go wrong? Carve-outs are complex. Standing up a separate debt stack while maintaining operational continuity carries execution risk, particularly if market conditions shift before an IPO window opens. The segment will also need to prove it can service its own debt independently of McKesson's broader cash flows.
The signal: Large healthcare conglomerates are increasingly unlocking value by separating business units and bringing in private capital partners before taking them public. Apollo's involvement signals institutional confidence in the medical-surgical distribution market — a space with steady demand and defensive characteristics.
McKesson's parent company reported a 6% rise in consolidated revenues to $79.3 billion and an 8% increase in adjusted earnings per diluted share to $7.88 in its first-quarter fiscal 2025 results. It has also boosted shareholder returns with a 15% dividend increase and a $4 billion expansion of its share repurchase programme.
The combination of strong financials, a marquee private equity partner, and a freshly structured credit facility suggests McKesson is building a clear runway for a medical-surgical IPO — one that could rank among the larger healthcare listings in recent years.
Read more: ainvest.com
